Beam Therapeutics Inc
BEAM20.010USD
+0.130+0.65%
收盘 07/03, 13:00（美东）报价延迟15分钟
2.01B总市值
亏损市盈率 TTM
关于 Beam Therapeutics Inc 公司
Beam Therapeutics Inc. 是一家通过碱基编辑开发精准基因药物的生物技术公司。该公司的基因编辑技术套件以碱基编辑为基础，该技术旨在实现目标基因组序列的精确、可预测和有效的单碱基变化，而不会在脱氧核糖核酸中造成双链断裂。其主要项目专注于镰状细胞病和 α-1 抗胰蛋白酶缺乏症，同时也在推进其他遗传疾病以及免疫学/肿瘤学方面的项目。其主要项目包括 BEAM-101、工程干细胞抗体配对逃避 (ESCAPE)、BEAM-302、BEAM-301 和 BEAM-201。BEAM-101 是一种针对患者的自体造血干细胞 (HSC) 研究疗法。ESCAPE 是一种潜在的无基因毒性 HSC 移植方法。 BEAM-302 是一种靶向肝脏的碱基编辑试剂脂质纳米颗粒制剂。BEAM-201 是一种抗 CD7 CAR-T 候选产品。
公司简介
公司代码BEAM
公司名称Beam Therapeutics Inc
上市日期Feb 06, 2020
成立日期2017
CEOMr. John M. Evans
员工数量483
证券类型Ordinary Share
年结日Feb 06
公司地址238 Main Street
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02142
电话18573278775
网址https://beamtx.com/
公司代码BEAM
上市日期Feb 06, 2020
成立日期2017
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Giuseppe Ciaramella, Ph.D.
Dr. Giuseppe Ciaramella, Ph.D.
President
President
107.78K
-6.45%
Dr. Amy Simon, M.D.
Dr. Amy Simon, M.D.
Chief Medical Officer
Chief Medical Officer
1.74K
-97.47%
Dr. Christine P. Bellon, Ph.D.
Dr. Christine P. Bellon, Ph.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Mr. Sravan K. Emany
Mr. Sravan K. Emany
Chief Financial and Principal Financial Officer
Chief Financial and Principal Financial Officer
--
--
Mr. John M. Evans
Mr. John M. Evans
Chief Executive Officer, Principal Accounting Officer, Director
Chief Executive Officer, Principal Accounting Officer, Director
--
--
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Independent Director
Independent Director
--
--
Ms. Christi Shaw
Ms. Christi Shaw
Independent Director
Independent Director
--
--
Dr. John Maraganore, Ph.D.
Dr. John Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Dr. Mark C. Fishman, M.D.
Dr. Mark C. Fishman, M.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Graham K. Cooper
Mr. Graham K. Cooper
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Giuseppe Ciaramella, Ph.D.
Dr. Giuseppe Ciaramella, Ph.D.
President
President
107.78K
-6.45%
Dr. Amy Simon, M.D.
Dr. Amy Simon, M.D.
Chief Medical Officer
Chief Medical Officer
1.74K
-97.47%
Dr. Christine P. Bellon, Ph.D.
Dr. Christine P. Bellon, Ph.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Mr. Sravan K. Emany
Mr. Sravan K. Emany
Chief Financial and Principal Financial Officer
Chief Financial and Principal Financial Officer
--
--
Mr. John M. Evans
Mr. John M. Evans
Chief Executive Officer, Principal Accounting Officer, Director
Chief Executive Officer, Principal Accounting Officer, Director
--
--
Mr. Chirfi Guindo
Mr. Chirfi Guindo
Independent Director
Independent Director
--
--
收入明细
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
暂无数据
地区USD
名称
营收
占比
United States
7.47M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 5月16日 周五
更新时间: 5月16日 周五
持股股东
股东类型
持股股东
持股股东
占比
Farallon Capital Management, L.L.C.
9.87%
The Vanguard Group, Inc.
8.80%
ARK Investment Management LLC
8.43%
Fidelity Management & Research Company LLC
7.56%
BlackRock Institutional Trust Company, N.A.
6.72%
Other
58.61%
持股股东
持股股东
占比
Farallon Capital Management, L.L.C.
9.87%
The Vanguard Group, Inc.
8.80%
ARK Investment Management LLC
8.43%
Fidelity Management & Research Company LLC
7.56%
BlackRock Institutional Trust Company, N.A.
6.72%
Other
58.61%
股东类型
持股股东
占比
Investment Advisor
38.62%
Investment Advisor/Hedge Fund
29.38%
Hedge Fund
20.30%
Venture Capital
4.83%
Research Firm
2.23%
Sovereign Wealth Fund
1.82%
Individual Investor
1.28%
Bank and Trust
0.46%
Pension Fund
0.31%
Other
0.77%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
531
99.92M
99.37%
+13.13M
2025Q1
562
100.13M
99.59%
+12.37M
2024Q4
542
80.18M
95.83%
-6.23M
2024Q3
539
78.60M
95.42%
-7.95M
2024Q2
538
78.23M
95.09%
-5.21M
2024Q1
550
76.09M
93.23%
-4.97M
2023Q4
549
75.48M
92.79%
-3.23M
2023Q3
554
74.84M
95.14%
-3.35M
2023Q2
566
72.06M
94.81%
-2.24M
2023Q1
583
68.81M
92.54%
-724.80K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Farallon Capital Management, L.L.C.
9.93M
9.87%
+1.69M
+20.50%
Mar 31, 2025
The Vanguard Group, Inc.
8.85M
8.8%
+1.24M
+16.36%
Mar 31, 2025
ARK Investment Management LLC
8.48M
8.43%
+1.41M
+19.98%
Mar 31, 2025
Fidelity Management & Research Company LLC
7.60M
7.56%
+4.49M
+144.60%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.76M
6.72%
+838.01K
+14.15%
Mar 31, 2025
ARCH Venture Partners
4.54M
4.51%
--
--
Mar 31, 2025
Nikko Asset Management Co., Ltd.
4.27M
4.24%
+309.26K
+7.81%
Mar 31, 2025
State Street Global Advisors (US)
3.44M
3.42%
+362.74K
+11.79%
Mar 31, 2025
T. Rowe Price Associates, Inc.
2.94M
2.93%
+1.27M
+75.83%
Mar 31, 2025
Kynam Capital Management LP
2.52M
2.5%
+762.01K
+43.39%
Mar 31, 2025
查看更多
持股ETF
更新时间: 7月2日 周三
更新时间: 7月2日 周三
机构名称
占比
ARK Genomic Revolution ETF
3.47%
Global X Genomics & Biotechnology ETF
1.9%
WisdomTree BioRevolution Fund
1.65%
ARK Innovation ETF
1.6%
Virtus LifeSci Biotech Clinical Trials ETF
0.65%
Franklin Genomic Advancements ETF
0.61%
SPDR S&P Biotech ETF
0.47%
NYLI Healthy Hearts ETF
0.33%
Direxion Daily S&P Biotech Bull 3X Shares
0.28%
iShares Health Innovation Active ETF
0.17%
查看更多
ARK Genomic Revolution ETF
占比3.47%
Global X Genomics & Biotechnology ETF
占比1.9%
WisdomTree BioRevolution Fund
占比1.65%
ARK Innovation ETF
占比1.6%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.65%
Franklin Genomic Advancements ETF
占比0.61%
SPDR S&P Biotech ETF
占比0.47%
NYLI Healthy Hearts ETF
占比0.33%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.28%
iShares Health Innovation Active ETF
占比0.17%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
